Physician profile
Niki Silverstein
NPI 1669478731
$4,167.24
in general payments reported to CMS, 2019-2025
24 companies · $592 in 2025
The $592 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $213 · 2021: $838 · 2022: $471 · 2023: $879 · 2024: $912 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,158.79 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $649.17 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Envista Aspire Iol |
| Johnson & Johnson Surgical Vision, INC. | $361.70 | 2020-2025 | Tecnis Iol |
| Abbvie INC. | $338.10 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $289.83 | 2021-2025 | Total30, Precision7 |
| Glaukos Corporation | $285.44 | 2019-2024 | |
| Kala Pharmaceuticals, INC. | $178.16 | 2020-2022 | |
| Allergan, INC. | $151.55 | 2019-2021 | |
| Rxsight INC | $130.49 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $95.93 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $89.04 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $72.36 | 2021-2025 | Acuvue |
| Oyster Point Pharma, INC. | $61.96 | 2022-2024 | Tyrvaya |
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Eyevance Pharmaceuticals LLC | $42.25 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $36.39 | 2024-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $29.17 | 2021-2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $28.76 | 2020-2021 | |
| Coopervision INC. | $27.61 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $21.12 | 2023 | Rayone Spheric, Omidria, Rayone Emv |
| Harrow Eye, LLC | $17.24 | 2024 | Vevye |
| Omeros Corporation | $15.37 | 2021 | |
| Shire North American Group INC | $14.78 | 2019 | |
| Sight Sciences, INC. | $13.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niki Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.